Exploring patients' reasons for discontinuance of heart medications.
BACKGROUND
Despite the importance of secondary prevention, nonadherence rates for patients with myocardial infarction (MI) range from 13% to 60% for prescribed, evidence-based medicines. Although rates and consequences of discontinuance vary for different medications, the existing literature provides little insight into reasons for discontinuance.


OBJECTIVE
To address this gap, we explored clopidogrel and cholesterol-lowering therapy (CLT) discontinuance after an MI to understand patients' reasons for stopping these 2 medications.


METHODS
In this qualitative descriptive study, 2 groups of patients who stopped a heart medication-either clopidogrel or CLT-were recruited from a prospective MI registry. Patients who discontinued CLT (n = 29) or clopidogrel (n = 11) were interviewed within 18 months of hospitalization. Patients were recruited and interviewed until data saturation was achieved. The Health Belief Model was used as an organizing framework in analyzing and coding the narrative data. The codes were then summarized for each group and compared to identify similarities and differences in reasons for CLT and clopidogrel discontinuance.


CONCLUSIONS
The most common reason for CLT discontinuance was adverse effects that were painful and interfered with daily life. Less common reasons for discontinuance were prescription confusion, cost, mistrust in medicines/healthcare system, and preference for alternative therapies. Reasons for clopidogrel discontinuance were duration confusion, adverse effects, and cost. Although doctors stopped patients' clopidogrel in preparation for surgery, doctors conceded to discontinuance of CLT for patients who experienced adverse effects after trying 2 to 3 different CLTs. Patients who discontinued CLT were more likely to believe that they did not need the treatment than do patients who discontinued clopidogrel. Clinicians should be aware that reasons may vary across patients and medication class for prematurely stopping therapy; thus, proactive interventions should be targeted to address these differences. Identifying at-risk patients for targeted interventions to prevent premature cardiac medication discontinuation is vital.
Garavalia
Linda
L
Department of Psychology, University of Missouri-Kansas City, Kansas City, MO, USA.
Garavalia
Brian
B
Spertus
John A
JA
Decker
Carole
C
D000368:Aged; D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000191:economics; D000077144:Clopidogrel; D005260:Female; D006801:Humans; D008297:Male; D055118:Medication Adherence / Q000523:psychology*; D008875:Middle Aged; D008960:Models, Psychological; D009042:Motivation; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy* / Q000401:mortality / Q000523:psychology*; D033262:Narration; D009730:Nursing Assessment; D015404:Nursing Methodology Research; D010353:Patient Education as Topic; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000191:economics; D036301:Qualitative Research; D018570:Risk Assessment; D011795:Surveys and Questionnaires; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000191:economics; D014481:United States / Q000453:epidemiology; D016903:Drug Monitoring
D000924:Anticholesteremic Agents; D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine
J Am Coll Cardiol. 2007 May 1;49(17):1753-62
17466224
Int Heart J. 2008 Mar;49(2):135-42
18475013
Int J Cardiol. 2008 Dec 17;131(1):97-104
18222551
J Gen Intern Med. 2004 Jun;19(6):638-45
15209602
Crit Care Nurse. 2008 Oct;28(5):54-64; quiz 65
18827087
Am Heart J. 2006 Jan;151(1):185-91
16368315
Arch Intern Med. 2006 Sep 25;166(17):1842-7
17000940
Arch Intern Med. 2005 Sep 12;165(16):1842-7
16157827
Health Educ Q. 1984 Spring;11(1):1-47
6392204
J Cardiovasc Nurs. 2008 Sep-Oct;23(5):414-21
18728514
Circulation. 2006 Jan 17;113(2):203-12
16401776
Pharmacotherapy. 2001 Jul;21(7):828-41
11444579
Ann Pharmacother. 2005 Nov;39(11):1792-7
16204391
Circulation. 2006 Jun 20;113(24):2803-9
16769908
Ann Pharmacother. 2007 Nov;41(11):1805-11
17925498
Circulation. 2003 Oct 7;108(14):1682-7
14504182
N Engl J Med. 1995 Apr 27;332(17):1125-31
7700285
Am J Med. 2004 Jul 15;117(2):73-81
15234641
JAMA. 2007 Feb 28;297(8):831-41
17327525
Circulation. 2006 May 16;113(19):2363-72
16702489
Ann Pharmacother. 2002 Oct;36(10):1532-9
12243601
Arch Intern Med. 2006 Sep 25;166(17):1855-62
17000942
Prog Cardiovasc Nurs. 2000 Summer;15(3):97-103
10951951
Arch Intern Med. 2007 Apr 23;167(8):847-52
17452550
Arch Intern Med. 1999 Aug 9-23;159(15):1793-802
10448784
Med J Aust. 1996 Feb 19;164(4):208-11
8604188
J Cardiovasc Nurs. 2008 May-Jun;23(3):250-7
18437067
Circulation. 2007 Feb 13;115(6):813-8
17224480
BMJ. 2000 Oct 21;321(7267):983-6
11039962
J Cardiovasc Nurs. 2007 Nov-Dec;22(6):459-65
18090186
Qual Health Res. 2003 Jul;13(6):781-820
12891715
N Engl J Med. 2005 Aug 4;353(5):487-97
16079372